We have spent years telling patients with PsA that weight loss may improve symptoms and reduce cardiometabolic risk. A new ACR 2026 abstract asks the more provocative question: could GLP-1–based therapy influence PsA outcomes even after accounting for the change on the scale?

Interstitial pneumonia with autoimmune features (IPAF) describes patients who have interstitial lung disease (ILD) plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease.

Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications?

IL-23 therapies are among the most efficacious and safest treatment options for patients with skin psoriasis. The enthusiasm for IL-23 agents for PsA is perhaps more tempered; while efficacy has been demonstrated for peripheral joint disease, there is concern that these agents are not effective in patients with axial disease.

Tsao et al presented abstract #2773 consensus recommendations for CAR-T cell therapy in the SARDs from the Taiwan College of Rheumatology. They are thorough and outline a sensible approach.